文献速递妇科产科

持续不明位置妊娠期待治疗与积极管理的成本效益分析

Cost-effectiveness analysis of expectant vs active management for treatment of persistent pregnancies of unknown location.
PubMed 文献 · Am J Obstet Gynecol · 2024-03-27

本研究为与多中心随机试验同步开展的前瞻性经济学评价,从医疗保健部门视角比较持续不明位置妊娠三种管理策略的成本效益。甲氨蝶呤平均成本最低(875美元),期待治疗平均质量调整生命年最高(0.1043),子宫 evacuation 成本最高且质量调整生命年最低。在支付意愿为每质量调整生命年15万美元时,期待治疗相比甲氨蝶呤不具有成本效益。

要点

  • 甲氨蝶呤平均成本最低(875美元),子宫 evacuation 成本最高(1902美元)。
  • 期待治疗平均质量调整生命年最高(0.1043),子宫 evacuation 最低(0.0992)。
  • 期待治疗输卵管切除率高于甲氨蝶呤(9.4% vs 1.2%)和子宫 evacuation(9.4% vs 8.1%)。

核心结论

  • 采用2剂甲氨蝶呤方案管理不明位置妊娠,相比期待治疗和子宫 evacuation 可能具有成本效益。
  • 尽管子宫 evacuation 被两种策略支配,但期待治疗与甲氨蝶呤的比较结果对甲氨蝶呤和手术管理治疗成本的适度变化敏感。

研究设计与样本

  • 本研究为与「期待治疗 versus 积极管理持续不明位置妊娠」多中心随机试验同步开展的前瞻性经济学评价,试验于2014年7月至2019年6月进行。
  • 参与者按1:1:1随机分配至期待治疗、2剂甲氨蝶呤或子宫 evacuation。
  • 分析采用医疗保健部门视角,时间范围为随机化后6周,成本以2018年美元表示。
  • 效果测量指标为质量调整生命年和输卵管切除率,并生成增量成本效益比和成本效益可接受性曲线。

主要发现

  • 甲氨蝶呤平均成本最低(875美元),其次为期待治疗(1085美元)和子宫 evacuation(1902美元)(P=.001)。
  • 期待治疗平均质量调整生命年最高(0.1043),其次为甲氨蝶呤(0.1031)和子宫 evacuation(0.0992)(P=.0001)。
  • 期待治疗输卵管切除率高于甲氨蝶呤(9.4% vs 1.2%,P=.02),也高于子宫 evacuation(9.4% vs 8.1%,P=.04)。
  • 子宫 evacuation 成本最高且质量调整生命年最低,被期待治疗和甲氨蝶呤两种策略支配。
  • 在基础案例分析中,支付意愿为每质量调整生命年15万美元时,期待治疗相比甲氨蝶呤不具有成本效益,增量成本效益比为每获得一个质量调整生命年175,083美元(95%CI,-1,666,825至2,676,375美元)。

关键数值与推荐

  • 阈值分析显示,甲氨蝶呤给药成本需达到214美元(增加16美元或8%)才有利于期待治疗。
  • 对于腹腔镜手术管理异位妊娠率不超过不明位置妊娠4%的低风险患者人群,期待治疗将更有利。
  • 基于成本效益可接受性曲线,在支付意愿为每获得一个质量调整生命年15万美元时,期待治疗相比甲氨蝶呤具有成本效益的概率为50%。
  • 结果取决于手术干预成本和预期甲氨蝶呤失败率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persistent pregnancies of unknown location are defined by abnormally trending serum human chorionic gonadotropin with nondiagnostic ultrasound. There is no consensus on optimal management. OBJECTIVE: This study aimed to assess the cost-effectiveness of 3 primary management strategies for persistent pregnancies of unknown location: (1) expectant management, (2) empirical 2-dose methotrexate, and (3) uterine evacuation followed by methotrexate, if indicated. STUDY DESIGN: This was a prospective economic evaluation performed concurrently with the Expectant versus Active Management for Treatment of Persistent Pregnancies of Unknown Location multicenter randomized trial that was conducted from July 2014 to June 2019. Participants were randomized 1:1:1 to expectant management, 2-dose methotrexate, or uterine evacuation. The analysis was from the healthcare sector perspective with a 6-week time horizon after randomization. Costs were expressed in 2018 US dollars. Effectiveness was measured in quality-adjusted life years and the rate of salpingectomy. Incremental cost-effectiveness ratios and cost-effectiveness acceptability curves were generated. Sensitivity analyses were performed to assess the robustness of the analysis. RESULTS: Methotrexate had the lowest mean cost ($875), followed by expectant management ($1085) and uterine evacuation ($1902) (P=.001). Expectant management had the highest mean quality-adjusted life years (0.1043), followed by methotrexate (0.1031) and uterine evacuation (0.0992) (P=.0001). The salpingectomy rate was higher for expectant management than for methotrexate (9.4% vs 1.2%, respectively; P=.02) and for expectant management than for uterine evacuation (9.4% vs 8.1%, respectively; P=.04). Uterine evacuation, with the highest costs and the lowest quality-adjusted life years, was dominated by both expectant management and methotrexate. In the base case analysis, expectant management was not cost-effective compared with methotrexate at a willingness to pay of $150,000 per quality-adjusted life year given an incremental cost-effectiveness ratio of $175,083 per quality-adjusted life year gained (95% confidence interval, -$1,666,825 to $2,676,375). Threshold analysis demonstrated that methotrexate administration would have to cost $214 (an increase of $16 or 8%) to favor expectant management. Moreover, expectant management would be favorable in lower-risk patient populations with rates of laparoscopic surgical management for ectopic pregnancy not exceeding 4% of pregnancies of unknown location. Based on the cost-effectiveness acceptability curves, the probability of expectant management being cost-effective compared with methotrexate at a willingness to pay of $150,000 per quality-adjusted life year gained was 50%. The results were dependent on the cost of surgical intervention and the expected rate of methotrexate failure. CONCLUSION: The management of pregnancies of unknown location with a 2-dose methotrexate protocol may be cost-effective compared with expectant management and uterine evacuation. Although uterine evacuation was dominated, expectant management vs methotrexate results were sensitive to modest changes in treatment costs of both methotrexate and surgical management.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Walter JR, Barnhart KT, Koelper NC, et al. Cost-effectiveness analysis of expectant vs active management for treatment of persistent pregnancies of unknown location. Am J Obstet Gynecol. 2024. PMID: 38552817. doi:10.1016/j.ajog.2024.03.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。